Poly (ADP-ribose) polymerase inhibitors for the treatment of ovarian cancer

Case scenario

Mrs Jones, aged 59, is a regular patient at your pharmacy. For the last few weeks she has come in almost daily to purchase various over the counter gastrointestinal products to relieve lower abdominal pain and bloating, along with nausea and dyspepsia. Today she comes in to ask you for something stronger, as she is not getting any relief from the products she has tried and her discomfort is severe. She also requests some Hiprex tablets, because she frequently feels the need to urinate. As you know Mrs Jones quite well, you can see she has lost weight in the last few weeks, but her abdomen is bloated. Mrs Jones tells you she does not have much of an appetite and feels full after a few bites of her food.

Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.  

Introduction

Ovarian cancer (OC) refers to a malignant tumour in one or both of the ovaries. It is the sixth leading cause of cancer deaths among females in Australia